Merck & Co., Inc. Financial Highlights Package First Quarter 2020 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q20 ........................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q19 ........................4 Table 3: Sales – Current Year and Prior Year by Quarter ...............5 Table 3a: Sales – U.S. / Ex- U.S. 1Q20............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .........................7 Table 4: Other (Income) Expense ....................................................8 -- 1 of 9 -- Sales 12,057 $ 10,816 $ 11% Costs, Expenses and Other Cost of sales (1) 3,312 3,052 9% Selling, general and administrative (1) 2,555 2,425 5% Research and development (1) 2,209 1,931 14% Restructuring costs (2) 72 153 -53% Other (income) expense, net (1) 71 188 -62% Income Before Taxes 3,838 3,067 25% Taxes on Income (1) 619 205 Net Income 3,219 2,862 12% Less: Net Loss Attributable to Noncontrolling Interests (1) - (53) Net Income Attributable to Merck & Co., Inc. 3,219 $ 2,915 $ 10% Earnings per Common Share Assuming Dilution 1.26 $ 1.12 $ 13% Average Shares Outstanding Assuming Dilution 2,547 2,603 Tax Rate (3) 16.1% 6.7% MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 (3) The effective income tax rate for the first quarter of 2019 reflects a net tax benefit of $360 million related to the settlement of certain federal income tax matters. (2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. 1Q19 1Q20 GAAP % Change (1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details. 1 -- 2 of 9 -- . . Sales 12,057 $ 10,816 $ 11,760 $ 12,397 $ 11,868 $ 46,840 $ 11% Costs, Expenses and Other Cost of sales 3,312 3,052 3,401 3,990 3,669 14,112 9% Selling, general and administrative 2,555 2,425 2,712 2,589 2,888 10,615 5% Research and development 2,209 1,931 2,189 3,204 2,548 9,872 14% Restructuring costs 72 153 59 232 194 638 -53% Other (income) expense, net 71 188 140 35 (223) 139 -62% Income Before Taxes 3,838 3,067 3,259 2,347 2,792 11,464 25% Taxes on Income 619 205 615 440 428 1,687 Net Income 3,219 2,862 2,644 1,907 2,364 9,777 12% Less: Net (Loss) Income Attributable to Noncontrolling Interests - (53) (26) 6 7 (66) Net Income Attributable to Merck & Co., Inc. 3,219 $ 2,915 $ 2,670 $ 1,901 $ 2,357 $ 9,843 $ 10% Earnings per Common Share Assuming Dilution 1.26 $ 1.12 $ 1.03 $ 0.74 $ 0.92 $ 3.81 $ 13% Average Shares Outstanding Assuming Dilution 2,547 2,603 2,588 2,572 2,559 2,580 Tax Rate 16.1% 6.7% 18.9% 18.7% 15.3% 14.7% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 2Q 3Q 4Q Full Year 1Q 1Q 1Q 2020 2019 % Change MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2 -- 3 of 9 -- Cost of sales 3,312 $ 296 68 364 2,948 $ Selling, general and administrative 2,555 278 11 289 2,266 Research and development 2,209 37 17 54 2,155 Restructuring costs 72 72 72 - Other (income) expense, net 71 (11) (11) 82 Income Before Taxes 3,838 (600) (168) (768) 4,606 Income Tax Provision (Benefit) 619 (158) (3) (7) (3) (165) 784 Net Income 3,219 (442) (161) (603) 3,822 Net Income Attributable to Merck & Co., Inc. 3,219 (442) (161) (603) 3,822 Earnings per Common Share Assuming Dilution 1.26 $ (0.18) (0.06) (0.24) 1.50 $ Tax Rate 16.1% 17.0% Only the line items that are affected by non-GAAP adjustments are shown. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in selling, general and administrative expenses reflect approximately $165 million of expenses related to the company's planned spin-off of Organon & Co., approximately $95 million of costs related to the acquisition of ArQule, Inc., and other acquisition and divestiture-related costs. Amounts included in research and development expenses primarily reflect expenses related to a net increase in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FIRST QUARTER 2020 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Adjustment Subtotal 3 -- 4 of 9 -- Cost of sales 3,052 $ 413 34 447 2,605 $ Selling, general and administrative 2,425 (1) (1) 2,426 Research and development 1,931 (31) (31) 1,962 Restructuring costs 153 153 153 - Other (income) expense, net 188 167 167 21 Income Before Taxes 3,067 (548) (187) (735) 3,802 Income Tax Provision (Benefit) 205 (98) (3) (31) (3) (293) (4) (422) 627 Net Income 2,862 (450) (156) 293 (313) 3,175 Less: Net (Loss) Income Attributable to Noncontrolling Interests (53) (53) (53) - Net Income Attributable to Merck & Co., Inc. 2,915 (397) (156) 293 (260) 3,175 Earnings per Common Share Assuming Dilution 1.12 $ (0.15) (0.06) 0.11 (0.10) 1.22 $ Tax Rate 6.7% 16.5% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP MERCK & CO., INC. GAAP TO NON-GAAP RECONCILIATION FIRST QUARTER 2019 (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b GAAP Acquisition and Divestiture-Related Costs (1) Restructuring Costs (2) Certain Other Items Adjustment Subtotal Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets recognized as a result of business acquisitions. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a net decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net primarily reflect goodwill impairment charges related to certain businesses in the Healthcare Services segment, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. (4) Includes a $360 million net tax benefit related to the settlement of certain federal income tax matters and a $67 million tax charge related to the finalization of treasury regulations associated with the 2017 enactment of U.S. tax legislation. 4 -- 5 of 9 -- 2020 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $12,057 $10,816 $11,760 $12,397 $11,868 $46,840 11 13 PHARMACEUTICAL 10,655 9,663 10,460 11,095 10,533 41,751 10 12 Oncology Keytruda 3,284 2,269 2,634 3,070 3,111 11,084 45 46 Alliance Revenue – Lynparza (2) 145 79 111 123 132 444 84 86 Alliance Revenue – Lenvima (2) 128 74 97 109 124 404 72 73 Emend 43 117 121 98 53 388 -63 -63 Vaccines (3) Gardasil / Gardasil 9 1,097 838 886 1,320 693 3,737 31 33 ProQuad / M-M-R II / Varivax 435 496 675 623 481 2,275 -12 -12 Pneumovax 23 256 185 170 237 334 926 39 40 RotaTeq 222 211 172 180 227 791 5 6 Vaqta 60 47 58 62 71 238 28 31 Hospital Acute Care Bridion 299 255 278 284 313 1,131 17 19 Noxafil 94 190 193 177 103 662 -50 -49 Invanz 64 72 78 57 57 263 -10 -7 Prevymis 60 32 38 45 50 165 88 90 Cancidas 55 61 67 62 58 249 -10 -8 Primaxin 51 59 71 77 67 273 -13 -11 Cubicin 46 88 67 52 50 257 -48 -46 Zerbaxa 37 26 27 35 32 121 40 42 Immunology Simponi 215 208 214 203 205 830 3 7 Remicade 88 123 98 101 89 411 -28 -27 Neuroscience Belsomra 79 67 76 80 83 306 18 18 Virology Isentress / Isentress HD 245 255 247 250 223 975 -4 -2 Zepatier 55 114 108 83 66 370 -52 -51 Cardiovascular Zetia 145 140 156 147 146 590 3 4 Vytorin 53 97 76 57 54 285 -45 -44 Atozet 122 94 92 97 108 391 30 34 Adempas (4) 56 48 53 57 57 215 18 20 Alliance Revenue - Adempas (5) 53 42 51 50 60 204 26 26 Diabetes (6) Januvia 774 824 908 807 943 3,482 -6 -5 Janumet 503 530 533 503 475 2,041 -5 -3 Women's Health Implanon / Nexplanon 195 199 183 199 206 787 -2 -1 NuvaRing 63 219 240 241 179 879 -71 -71 Diversified Brands Singulair 155 191 160 152 195 698 -19 -17 Cozaar / Hyzaar 102 103 109 116 113 442 -1 1 Nasonex 71 96 72 58 67 293 -26 -25 Arcoxia 70 75 75 72 67 288 -6 -4 Follistim AQ 41 57 63 62 58 241 -28 -27 Other Pharmaceutical (7) 1,194 1,082 1,203 1,149 1,183 4,615 10 12 ANIMAL HEALTH 1,214 1,025 1,124 1,122 1,122 4,393 18 21 Livestock 739 611 671 726 777 2,784 21 24 Companion Animals 475 414 453 396 345 1,609 15 17 Other Revenues (8) 188 128 176 180 213 696 47 33 (6) Total Diabetes sales were $1,353 million in the first quarter of 2020 and $1,402 million, $1,480 million, $1,360 million and $1,472 million for the first, second, third and fourth quarters of 2019, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of Healthcare Services segment revenues, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $2,155 million in the first quarter of 2020 and $1,887 million, $2,037 million, $2,517 million and $1,928 million for the first, second, third and fourth quarters of 2019, respectively. (4) Net product sales in Merck's marketing territories. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 2019 1Q MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 5 -- 6 of 9 -- 1Q 2020 1Q 2019 % Change 1Q 2020 1Q 2019 % Change 1Q 2020 1Q 2019 % Change TOTAL SALES (1) $12,057 $10,816 11 $5,137 $4,555 13 $6,920 $6,261 11 PHARMACEUTICAL 10,655 9,663 10 4,714 4,215 12 5,941 5,448 9 Oncology Keytruda 3,284 2,269 45 1,906 1,284 48 1,378 985 40 Alliance Revenue - Lynparza (2) 145 79 84 85 50 68 60 29 111 Alliance Revenue - Lenvima (2) 128 74 72 90 50 79 38 24 58 Emend 43 117 -63 5 63 -92 38 53 -29 Vaccines (3) Gardasil / Gardasil 9 1,097 838 31 461 362 27 636 476 34 ProQuad / M-M-R II / Varivax 435 496 -12 333 343 -3 102 153 -33 Pneumovax 23 256 185 39 182 125 45 75 59 26 RotaTeq 222 211 5 140 154 -9 82 57 44 Vaqta 60 47 28 30 29 5 30 18 63 Hospital Acute Care Bridion 299 255 17 143 119 20 157 136 15 Noxafil 94 190 -50 8 91 -92 87 99 -12 Invanz 64 72 -10 6 14 -58 59 58 1 Prevymis 60 32 88 26 18 49 33 14 136 Cancidas 55 61 -10 3 1 133 52 60 -13 Primaxin 51 59 -13 51 59 -13 Cubicin 46 88 -48 15 42 -65 31 46 -31 Zerbaxa 37 26 40 20 12 63 16 14 20 Immunology Simponi 215 208 3 215 208 3 Remicade 88 123 -28 88 123 -28 Neuroscience Belsomra 79 67 18 27 24 14 53 44 20 Virology Isentress / Isentress HD 245 255 -4 75 108 -30 170 147 16 Zepatier 55 114 -52 18 33 -46 37 81 -54 Cardiovascular Zetia 145 140 3 (2) * 147 140 5 Vytorin 53 97 -45 3 3 18 50 94 -47 Atozet 122 94 30 122 94 30 Adempas (4) 56 48 18 56 48 18 Alliance Revenue - Adempas (5) 53 42 26 49 40 20 5 2 133 Diabetes (6) Januvia 774 824 -6 355 384 -7 419 440 -5 Janumet 503 530 -5 113 167 -32 390 364 7 Women's Health Implanon / Nexplanon 195 199 -2 149 149 45 50 -10 NuvaRing 63 219 -71 26 185 -86 37 34 8 Diversified Brands Singulair 155 191 -19 5 5 -11 151 186 -19 Cozaar / Hyzaar 102 103 -1 7 4 78 95 99 -4 Nasonex 71 96 -26 6 (1) * 65 97 -33 Arcoxia 70 75 -6 70 75 -6 Follistim AQ 41 57 -28 21 29 -30 21 28 -25 Other Pharmaceutical (7) 1,194 1,082 10 409 328 25 780 754 3 ANIMAL HEALTH 1,214 1,025 18 384 294 31 830 731 13 Livestock 739 611 21 162 117 39 577 494 17 Companion Animals 475 414 15 222 177 25 253 237 7 Other Revenues (8) 188 128 47 39 46 -15 149 82 80 * 200% or greater (4) Net product sales in Merck's marketing territories. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Total Diabetes sales were $1,353 million and $1,402 million on a global basis for first quarter 2020 and 2019, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of Healthcare Services segment revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. (3) Total Vaccines sales were $2,155 million and $1,887 million on a global basis for first quarter 2020 and 2019, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2020 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- 2020 1Q 1Q 2Q 3Q 4Q Full Year TOTAL PHARMACEUTICAL $10,655 $9,663 $10,460 $11,095 $10,533 $41,751 10 United States (1) 4,714 4,215 4,807 5,180 4,751 18,953 12 % Pharmaceutical Sales 44.2% 43.6% 46.0% 46.7% 45.1% 45.4% Europe (2) 2,543 2,335 2,301 2,304 2,373 9,314 9 % Pharmaceutical Sales 23.9% 24.2% 22.0% 20.8% 22.5% 22.3% China 846 725 745 898 773 3,141 17 % Pharmaceutical Sales 7.9% 7.5% 7.1% 8.1% 7.3% 7.5% Japan 789 779 900 894 921 3,494 1 % Pharmaceutical Sales 7.4% 8.1% 8.6% 8.1% 8.7% 8.4% Asia Pacific (other than China and Japan) 613 642 606 638 614 2,500 -4 % Pharmaceutical Sales 5.8% 6.6% 5.8% 5.8% 5.8% 6.0% Eastern Europe/Middle East Africa 490 343 388 423 423 1,577 43 % Pharmaceutical Sales 4.6% 3.6% 3.7% 3.8% 4.0% 3.8% Latin America 419 427 523 534 429 1,914 -2 % Pharmaceutical Sales 3.9% 4.4% 5.0% 4.8% 4.1% 4.6% Canada 212 177 179 211 216 783 20 % Pharmaceutical Sales 2.0% 1.8% 1.7% 1.9% 2.0% 1.9% Other (1) 29 20 11 13 33 75 45 % Pharmaceutical Sales 0.3% 0.2% 0.1% 0.1% 0.3% 0.2% % Change 1Q Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Alliance revenue related to Adempas attributable to the United States has been reclassified from Other. (2) Europe primarily represents all European Union countries and the European Union accession markets. MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 2019 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q20 1Q19 Interest income (25) $ (89) $ Interest expense 212 209 Exchange losses 54 101 (Income) loss from investments in equity securities, net (1) (52) 25 Net periodic defined benefit plan (credit) cost other than service cost (90) (141) Other, net (28) 83 Total 71 $ 188 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --